MacroGenics
Clinical trials sponsored by MacroGenics, explained in plain language.
Biopharmaceutical company developing antibody-based cancer therapies.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New Antibody-Drug conjugate targets Hard-to-Treat cancers Results expected Nov 2026 (estimated)
- New hope for tough blood cancers: experimental drug MGD024 enters human testing Results expected Nov 2026 (estimated)
- New drug lorigerlimab takes on Platinum-Resistant ovarian cancer Results expected Jul 2027 (estimated)
-
New drug combo aims to slow advanced prostate cancer
Disease control CompletedThis study tests whether adding an immunotherapy drug called lorigerlimab to standard chemotherapy (docetaxel) can help men with a tough-to-treat type of prostate cancer live longer without their disease getting worse. About 150 men with metastatic castration-resistant prostate c…
Phase 2 • Sponsor: MacroGenics • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Experimental drug duo targets Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested a combination of two experimental drugs, vobramitamab duocarmazine and lorigerlimab, in 31 people with advanced solid tumors like prostate, melanoma, and pancreatic cancer. The main goal was to check safety and find the right dose. Participants recei…
Phase 1 • Sponsor: MacroGenics • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC